Amarin Corp Plc (AMRN)

[venus537]

"REDUCE-IT label looks like more stronger than MARINE label. (Both as infringement and patent validity.)"

Hence, the opinion of why many of us think the generics are going after the MARINE patents as a way to circumvent the Reduce-It indication. Yes, I understand your point that the generics couldn't go after the Reduce-It patents until the Reduce-It label was approved but that's beside the point IMO.

Since we're talking about the same exact drug for both indications and since this would have the effect of allowing doctors to prescribe Vascepa "widely" under the guise of the MARINE indication then we're (investors) potentially royally screwed if the court only rules in isolation of the MARINE patents.

But you're only the messenger and I thank you and others for pointing this out and I have to reevaluate my position in Amarin. A loss in court will hurt me a lot more than the gain from a win.